Ascentage Pharma Group International (AAPG) revenue breakdown
By product, Intellectual Property is the largest at 69% of fiscal 2024 revenue; Products grew fastest, 22% a year over 2 years.
By region, Switzerland is the largest at 69% of fiscal 2024 revenue; Chinese mainland grew fastest, 44% a year over 1 years.
Revenue by product
Fiscal years, as Ascentage Pharma Group International reports them in its 10-K filings; fiscal 2024 total $981M.
| Products | 2022 | 2023 | 2024 | Share |
|---|---|---|---|---|
| Intellectual Property | — | — | $678M | 69% |
| Products | $175M | $194M | $261M | 27% |
| Others | $35M | $28M | $41M | 4% |
Revenue by region
Fiscal years, as Ascentage Pharma Group International reports them in its 10-K filings; fiscal 2024 total $981M.
| Regions | 2022 | 2024 | Share |
|---|---|---|---|
| Switzerland | — | $678M | 69% |
| Chinese mainland | $210M | $302M | 31% |
| United States | $4,000 | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for AAPG.
Open AAPG in InvestinglyQuestions
Where does Ascentage Pharma Group International make its money?
In fiscal 2024, by product: Intellectual Property $678M, Products $261M, Others $41M.
From Ascentage Pharma Group International's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.